Helicobacter pylori erradication and its relation to antibiotic resistance and CYP2C19 status;Erradicación de H. pylori y su relación con la resistencia a los antibióticos y el estatus de CYP2C19

Revista Espanola de Enfermedades Digestivas

Volumn 99, Issue 2, 2007, Pages 71-75

  Garza Gonzalez E ^a   Giasi Gonzalez E ^b   Martinez Vazquez M A ^b   Perez Perez G I ^c   Gonzalez G M ^a   Maldonado Garza, H J ^b   Bosques Padilla, Francisco J ^b  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c Universidad de Nueva York   (United States)

Author keywords

Amoxicillin; Antibiotic resistance; Clarithromycin; CYP2C19; Helicobacter pylori; Rabeprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; RABEPRAZOLE; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; CYP2C19 PROTEIN, HUMAN; MIXED FUNCTION OXIDASE; UNCLASSIFIED DRUG; UNSPECIFIC MONOOXYGENASE;

ADULT; AGAR DILUTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ERADICATION THERAPY; FEMALE; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; MICROBIOLOGICAL EXAMINATION; STATISTICAL ANALYSIS; TIME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; DATA INTERPRETATION, STATISTICAL; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIXED FUNCTION OXYGENASES; TIME FACTORS;

EID: 34249676929     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, et al. European Helicobacter pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection-The Maastricht 2-2000 Consensus report. Aliment Pharmacol Ther 2002; 16: 167-80.
2. McLoughlin R, Racz I, Buckley M, O'Connor HJ, O'Morain C. Therapy of Helicobacter pylori. Helicobacter 2004; 9 (Supl. 1): 42-8.
3. Bytzer P, O'Morain C. Treatment of Helicobacter pylori. Helicobacter 2005; 10 (Supl. 1): 40-6.
4. Savarino V, Neri M, Vigneri S. PPI-based triple therapy in the eradication of H. pylori infection. Gastroenterology 1999; 117: 746-7.
5. Sung JY, Leung WK, Ling TK, Yung MY, Chan FK, Lee YT, et al. One week use of ranitidine bismuth citrate, amoxicilina and claritromicina for the treatment of Helicobacter pylori related duodenal ulcer. Aliment Pharmacol Ther 1998; 12: 723-30.
6. Furuta T, Sagehashi Y, Shirai N, Sugimoto M, Nakamura A, Kodaira M, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005; 3: 564-73.
7. González HM, Romero EM, Peregrina AA, de J Chávez T, Escobar-Islas E, Lozano F, et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans. J Clin Pharmacol 2003; 43: 1211-5.
8. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002; 17: 748-53.
9. Kawabata H, Habu Y, Tomioka H, Kutsumi H, Kobayashi M, Oyasu K, et al. Effect of different proton pump inhibitors, differences in CYP2C19 genotype and antibiotic resistance on the eradication rate of Helicobacter pylori infection by a 1-week regimen of proton pump inhibitor, amoxicilina and claritromicina. Aliment Pharmacol Ther 2003; 17: 259-64.
10. Ieiri I, Kubota T, Urae A, Kimura M, Wada Y, Mamiya K, et al. Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alelos, C gamma P2C19m1 in exon 5 and C gamma P2C19m2 in exon 4, in Japanese subjects. Clin Pharmacol Ther 1996; 59: 647-53.
11. Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, et al. Effects of rabeprazol, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-7.
12. Shirai N, Furuta T, Mmoriyama Y, Okochi H. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazol on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37.
13. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, et al. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002; 17: 748-53.
14. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-67.
15. Georgopoulos SD, Ladas SD, Karatapanis S, Mentis A, Spiliadi C, Artikis V, et al. Factors that may affect treatment outcome of triple Helicobacter pylori eradication therapy with omeprazole, amoxicilina, and claritromicina. Dig Dis Sci 2000; 45: 63-7.
16. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001; 41: 815-50.
17. Flores-Orta D, Bosques-Padilla F, Gómez-Leija, Frederick F. Comparative study of rapid urease test (Hazell test) vs. CLO-test in the diagnosis of Helicobacter pylori infection. Gut 1997; 41 (Supl. 3): A160.
18. Pérez-Pérez GI. Accurate diagnosis of Helicobacter pylori. Culture, including transport. Gastroenterology Clinics of NorthAmerica 2000; 29: 879-84.
19. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing and approved standard M7-A5. Informational supplement M100-S10.22. National Committee for Clinical Laboratory Standards, Wayne, Pa. 2000.
20. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994; 46: 594-8.
21. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin in humans. J Biol Chem 1994; 269: 15419-22.
22. Garza-González E, Pérez-Pérez GI, Alanis-Aguilar O, Tijerina-Menchaca R, Maldonado-Garza HJ, Bosques-Padilla FJ. Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico. J Chemother 2002; 14: 342-5.